Lifecore Biomedical Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lifecore Biomedical Inc 's ROA in the first quarter of 2026?
Lifecore Biomedical Inc recorded a cumulative net loss of $-46 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -19.62%.

However, within the Healthcare sector 355 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from to 3442.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Sep 30 2025) I. Quarter	(May 25 2025) IV. Quarter	(Feb 23 2025) III. Quarter	(Nov 24 2024) II. Quarter
Y / Y Total Assets Change	-11.21 %	-4.71 %	-12.84 %	-3.47 %	0.16 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-46	-39	-44	-49	-16
Return On Assets (TTM)	-19.62 %	-16.06 %	-18.07 %	-19.45 %	-6.41 %
LFCR's Total Ranking	# 3442	#	# 3458	# 3534	# 3619
Total Assets (TTM) in million	225	235	239	238	254
Seq. Total Assets Change	-4.13 %	-1.73 %	0.69 %	-6.41 %	2.89 %
Seq. Net Income Change	-	-	-	-	-

LFCR's 5 Years Annual ROA >> Back to LFCR Management Effectiveness >> Compare LFCR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 128
Sector	# 356
Overall	# 3412

Return On Assets Statistics
High	Average	Low
4.81 %	-26.07 %	-63.84 %
(May 26 2024)		(Aug 27 2023)

Financial Statements
Lifecore Biomedical Inc 's Assets	$ 225 million	LFCR's Balance sheet
Lifecore Biomedical Inc 's Income	$ -16 million	Quarterly LFCR's Income Statement
LFCR's Income by Division		See LFCR's Income by Division

Annual Return On Assets	(May 25 2025) FY 2025	(May 26 2024) FY 2024	(May 28 2023) FY 2023	(May 29 2022) FY 2022	FY
Y / Y Total Assets Change	-5.76 %	0.16 %	-8.73 %	-43.49 %	-9.18 %
Total Assets in million	239	254	254	278	492
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-44	12	-100	-115	0
Annual Return On Assets	-18.45 %	4.73 %	-39.27 %	-41.28 %	-

LFCR's 5 Years Annual ROA >> Back to LFCR Management Effectiveness >> Compare LFCR ROA to its Competitors

More Return On Assets Ratios
LFCR's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LFCR's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LFCR's Competitors
Subscribers only: Roa for Lifecore Biomedical Inc 's Suppliers
Subscribers only: Return On Assets for LFCR's Customers

You may also want to know
LFCR's Roi	LFCR's Inventory Turnover Ratio	LFCR's Growth Rates	LFCR's Dividend Comparisons
	LFCR's Profitability Ratios	LFCR's Asset Turnover Ratio	LFCR's Dividend Growth
LFCR's Roe	LFCR's Valuation Ratios	LFCR's Financial Strength Ratios	LFCR's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:10:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.